PomegaMD

Tzeira Sofer is a health industry visionary whose life mission has been to create a stable, safe and effective healing system based on the omega-5 fatty acid punicic acid.  Pomega is the culmination of her efforts to ensure optimal skin health for all people.

Dr. Mitchel P. Goldman is a world-renowned, double-board certified dermatologist and cosmetic surgeon who started practicing medicine in 1986. Recognized by the American Board of Dermatology and the American Board of Cosmetic Surgery, Dr. Goldman graduated from Boston University (Summa Cum Laude and Phi Beta Kappa) and Stanford University Medical School.

Dr. Lawrence F. Eichenfield is Chief of Pediatric and Adolescent Dermatology at Rady Children’s Hospital–San Diego, Vice Chair of the Department of Dermatology, and Professor of Dermatology and Pediatrics at the University of California, San Diego (UCSD) School of Medicine. He received his medical degree from Mount Sinai School of Medicine in New York, was a pediatric resident and Chief Resident at Children’s Hospital of Philadelphia and completed his dermatology residency at the Hospital of the University of Pennsylvania.

Phil Rose is the founder of Rose and Company, a commercialization consulting group for companies offering oral and dermatology products. A licensed pharmacist, he has over 30 years of experience as an executive with GSK, Bausch Health Care, and Obagi Medical Products.

Adam Frank is Chief Financial Officer for Pomega, where he is responsible for finance, operations and business development/strategy. He has had a distinguished career in the luxury cosmetics industry, including more than 20 years as the VP Finance and Business Operations for Estee Lauder, North America, COO of LVMH’s Beauty Division, Guerlain, USA and VP of Finance for YSL Beaute, a division of the Gucci Group.

Stuart McFaul is the founder of Spiralgroup, a leading brand marketing company. With over 40 years experience, he is an international marketing expert who has guided B2B / B2C for over 200 companies all over the world, including Apple, Cisco, Getty Images, HP, Oracle and numerous other startups.

Abraham Sofer is General Counsel for Pomega. As principal of his DC-based firm, he is an accomplished senior executive, advisor, and general counsel with more than 35 years of experience with innovative technologies companies in biotech, fintech, greentech, and financial industries. He is on the advisory board of several companies and is a current active member of the New York State Bar and the District of Columbia Bar.

Dr. Jaggi Rao is a board-certified dermatologist licensed in both Canada and the United States. He is also a certified cosmetic and laser surgeon, having completed an accredited fellowship in 2004 with the American Academy of Cosmetic Surgery in southern California.

Dr. Douglas C. Wu is a double board-certified dermatologist in both Canada and the United States with specialty training in cosmetic surgery via the prestigious American Society of Dermatologic Surgery Fellowship program. Dr. Wu has authored numerous medical articles and textbook chapters in both general and aesthetic dermatological literature and has lectured at major conferences across the globe.

Tom White is a co-founder/CEO of TriAct Therapeutics, a Phase 3 clinical stage cancer therapeutics company. He has served in operating, commercial strategy and marketing leadership positions for 30+ years, including acting as CEO of BiPar Sciences, a venture-backed cancer therapeutics company that was sold to Sanofi for $500MM and Senior VP Commercial Strategy/CRO/CMO for Shaman Pharmaceuticals.

Dr. Hanan Osman-Ponchet. Founder and CEO of PKDERM Labs. With over 20 years of experience working with pharmaceutical companies, and serving recently as Metabolism Manager at Galderma, and previously as In Vitro DMPK Manager with Sanofi, Hanan’s fields of interest in skin sciences and dermatology include evaluating metabolism and pharmacokinetics, developing in vitro models for testing efficacy and safety of skin products, researching the role of drug transporters in the disposition of topical drugs and in skin cancer diagnosis and treatment, developing innovative tools to avoid infection of skin with SARS-CoV-2, and treating Covid-19 pathology.

Dr. Jean Paul Thenot, is an expert in pharmaceutical development with a focus on preclinical pharmacokinetics (PK) and metabolism (M). After 10 years in North-America holding several academic positions, he assumed the role of MPK Director at Sanofi France where he worked between 1981-2007. A honorary president of the GMP organization in France, Jean-Paul has been serving as a teaching professor in Vietnam since 2012 at the several universities, and in Algeria since 2016 at the Etude de Bioéquivalence. He has authored over 100 publications and his expertise also includes drug research & development and evaluation of licensing opportunities (MPK aspects). He has served as consultant to various pharmaceuticals companies since 2008.